Myovant Sciences announced Sunday it formed a special committee of independent directors to assess Sumitovant Biopharma’s offer to acquire the company, and ultimately, turned the offer down.
https://www.pharmalive.com/wp-content/uploads/2022/10/BioSpaceDavidMarek10-3-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-03 08:45:532022-10-03 11:24:26Myovant turns down acquisition offer from largest stakeholder
